A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis (BREEZE-AD6)

I4V-MC-JAIX -

This open-label study will evaluate the long-term efficacy and safety of baricitinib in adult participants with moderate to severe atopic dermatitis (AD), who have completed participation in study BREEZE-AD5/Study JAIW (NCT03435081).

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Atopic Dermatitis (Eczema)
What the trial is testing?
Baricitinib
Could I receive a Placebo?
No
Enrollment Goal
374
Trial Dates
Jun 27, 2018 - Jun 13, 2022
How long will I be in the trial?
This 204-week outpatient study, includes a treatment period of approximately 200-weeks and up to 17 planned study visits.
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participants must have completed at least 16 weeks of treatment in study JAIW prior to discontinuation

  • Female participants must not be pregnant or breastfeeding

  • Participants must be willing to commit to using birth control for the duration of the study, unless pregnancy is not possible for the participant or the participants female sexual partner

Participants Must Not:

  • Participants must not be enrolled in other studies that may not be compatible with study JAIX.

  • Participants must not have uncontrolled high blood pressure, heart attack, chest pain, stroke, heart failure or any other serious or unstable disease or infection

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.